CoChat
Sign Up
Cited by 830

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer

Misra, Suniti, Hascall, Vincent C., Markwald, Roger R., Ghatak, Shibnath·2015·Frontiers in Immunology
DOI 10.3389/fimmu.2015.00201PMC PMC4422082
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2015.00201

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Native polymeric HA and degraded HA fragments. High molecular weight (HMW ≥ 500 disaccharide units; [β-1, 4-GlcUA-β-1, 3-GlcNAc]n synthesized in the normal homeostatic condition is degraded by free radicals and hyaluronidases (HYAL1-2) during inflammation/tumorigenesis when tissue injury occurs. These fragments are ≤50 disaccharide units. As a result, the fragments of different molecular weights have different biological functions. For example, intermediate fragments (30–500 kDa) can stimulate cell proliferation while smaller fragments <50 kDa promote cell migration. HA oligosaccharides down to three disaccharides can still bind to CD44.
Figure 1 Native polymeric HA and degraded HA fragments. High molecular weight (HMW ≥ 500 disaccharide units; [β-1, 4-GlcUA-β-1, 3-GlcNAc]n synthesized in the normal homeostatic condition is degraded by free radicals and hyaluronidases (HYAL1-2) during inflammation/tumorigenesis when tissue injury occurs. These fragments are ≤50 disaccharide units. As a result, the fragments of different molecular weights have different biological functions. For example, intermediate fragments (30–500 kDa) can stimulate cell proliferation while smaller fragments <50 kDa promote cell migration. HA oligosaccharides down to three disaccharides can still bind to CD44.CC BY · PubMed Central
Figure 2 (A) Mouse CD44 and RHAMM gene/protein structures in mice. Model structure of alternative splicing in CD44. CD44 pre-mRNA is encoded by 20 exons in mouse and 19 exons in human being. The common standard CD44s (hematopoietic) form contains no extra exons, and the protein has a serine motif encoded in exon 5 that can initiate synthesis of a chondroitin sulfate or dermatan sulfate chain. Alternative splicing of CD44 predominantly involves variable insertion of 10 extra exons with combinations of exons 6–15 and spliced in v1–v10 into the stem region, of which v3 encodes a substitution site for a heparan sulfate chain. Variable numbers of the v exons can be spliced in epithelial cells, endothelial cells, and inflammatory monocytes and also are upregulated commonly on neoplastic transformation depending on the tissue. (B) Model structure of alternatively spliced CD44 proteins. The CD44 protein is composed of an extracellular N-terminal domain, a stem region in the extracellular domain close to the transmembrane region, where the variant exon products (red/violet circles) are inserted, the transmembrane region, and the carboxyl terminal cytoplasmic tail. There are multiple sites for N-glycosylation (purple circles) and O-glycosylation (orange circles), and a sulfation domain. The N-terminal portion contains highly conserved disulfide bonds as well as 2 BX7B motifs, both of which are essential for HA binding. CD44 is subjected to extensive glycosylation, sulfation, and attachment of GAGs that contribute to regulation of the HA-binding activity. The C-terminal cytoplasmic tail contains several phosphorylation sites that regulate the interaction of CD44 with the cytoskeletal linker proteins, as well as with SRC kinases. (C) RHAMM exon structure. The full-length protein (85 kDa in human beings) is largely associated with microtubule formation during the cell cycle progression. Three isoforms are generated by alternative splicing of exon 4, 5, or 13. Loss of exon 4 disrupts association with microtubules and results in the appearance of RHAMM in the cell nucleus. N-terminal truncations that may be generated by a posttranslational mechanism are constitutively present in some aggressive breast cancer cell lines and tumors. These accumulate in the nucleus and on the cell surface. (D) The secondary structure of RHAMM. RHAMM can self-associate to form random coiled coils (132).
Figure 2 (A) Mouse CD44 and RHAMM gene/protein structures in mice. Model structure of alternative splicing in CD44. CD44 pre-mRNA is encoded by 20 exons in mouse and 19 exons in human being. The common standard CD44s (hematopoietic) form contains no extra exons, and the protein has a serine motif encoded in exon 5 that can initiate synthesis of a chondroitin sulfate or dermatan sulfate chain. Alternative splicing of CD44 predominantly involves variable insertion of 10 extra exons with combinations of exons 6–15 and spliced in v1–v10 into the stem region, of which v3 encodes a substitution site for a heparan sulfate chain. Variable numbers of the v exons can be spliced in epithelial cells, endothelial cells, and inflammatory monocytes and also are upregulated commonly on neoplastic transformation depending on the tissue. (B) Model structure of alternatively spliced CD44 proteins. The CD44 protein is composed of an extracellular N-terminal domain, a stem region in the extracellular domain close to the transmembrane region, where the variant exon products (red/violet circles) are inserted, the transmembrane region, and the carboxyl terminal cytoplasmic tail. There are multiple sites for N-glycosylation (purple circles) and O-glycosylation (orange circles), and a sulfation domain. The N-terminal portion contains highly conserved disulfide bonds as well as 2 BX7B motifs, both of which are essential for HA binding. CD44 is subjected to extensive glycosylation, sulfation, and attachment of GAGs that contribute to regulation of the HA-binding activity. The C-terminal cytoplasmic tail contains several phosphorylation sites that regulate the interaction of CD44 with the cytoskeletal linker proteins, as well as with SRC kinases. (C) RHAMM exon structure. The full-length protein (85 kDa in human beings) is largely associated with microtubule formation during the cell cycle progression. Three isoforms are generated by alternative splicing of exon 4, 5, or 13. Loss of exon 4 disrupts association with microtubules and results in the appearance of RHAMM in the cell nucleus. N-terminal truncations that may be generated by a posttranslational mechanism are constitutively present in some aggressive breast cancer cell lines and tumors. These accumulate in the nucleus and on the cell surface. (D) The secondary structure of RHAMM. RHAMM can self-associate to form random coiled coils (132).CC BY · PubMed Central
Figure 3 The involvement of HA and CD44 in cell survival and differentiation. (A) Model for the involvement of CD44v6 and Met due to autocrine TGF β1 signaling in lung fibrogenic fibroblasts. The repetitive lung injury in pulmonary fibrosis results in overexpression of TGFβ1 and TGFβ1-induced autocrine signaling that induces a sustained expression of CD44v6 and its co-receptor c-Met. This activates fibrogenic lung fibroblasts with subsequent increased collagen matrix synthesis. Therefore, TGF β1-induced CD44v6 and Met can have a crucial role for the sustained fibrogenic activation of lung fibroblasts. The CD44-phosphorylated ERM complex initiates activation of transforming growth factor-β receptor 1 and 2 (TGFβRI and II) and the downstream SMAD signaling complex, which contribute to fibrosis. (B) Model for involvement of periostin in HA-CD44-mediated cell survival and differentiation. Matricellular protein [periostin (PN)] binding to β1 or β3-integrin activates FAK, which activates downstream MAPK/Erk and PI3K/Akt to regulate cardiac valve cell growth, survival, differentiation into fibroblasts, and matrix organization (maturation). PN binding to β3-integrin also activates Has2 mRNA expression, Has2 phosphorylation, and HA synthesis. The interaction of HA with CD44, may, in turn, amplify the downstream effects of PN on heart valve cushion cell differentiation/maturation processes. (C) Cleavage of the extracellular domain is accompanied by the cleavage of the intracellular domain (ICD) by the presenilin-γ-secretase complex. The CD44 ICD acts together with CBP or p300 as a transcription factor and promotes CD44 transcription and extracellular matrix production.
Figure 3 The involvement of HA and CD44 in cell survival and differentiation. (A) Model for the involvement of CD44v6 and Met due to autocrine TGF β1 signaling in lung fibrogenic fibroblasts. The repetitive lung injury in pulmonary fibrosis results in overexpression of TGFβ1 and TGFβ1-induced autocrine signaling that induces a sustained expression of CD44v6 and its co-receptor c-Met. This activates fibrogenic lung fibroblasts with subsequent increased collagen matrix synthesis. Therefore, TGF β1-induced CD44v6 and Met can have a crucial role for the sustained fibrogenic activation of lung fibroblasts. The CD44-phosphorylated ERM complex initiates activation of transforming growth factor-β receptor 1 and 2 (TGFβRI and II) and the downstream SMAD signaling complex, which contribute to fibrosis. (B) Model for involvement of periostin in HA-CD44-mediated cell survival and differentiation. Matricellular protein [periostin (PN)] binding to β1 or β3-integrin activates FAK, which activates downstream MAPK/Erk and PI3K/Akt to regulate cardiac valve cell growth, survival, differentiation into fibroblasts, and matrix organization (maturation). PN binding to β3-integrin also activates Has2 mRNA expression, Has2 phosphorylation, and HA synthesis. The interaction of HA with CD44, may, in turn, amplify the downstream effects of PN on heart valve cushion cell differentiation/maturation processes. (C) Cleavage of the extracellular domain is accompanied by the cleavage of the intracellular domain (ICD) by the presenilin-γ-secretase complex. The CD44 ICD acts together with CBP or p300 as a transcription factor and promotes CD44 transcription and extracellular matrix production.CC BY · PubMed Central
Figure 4 CD44- and CD44v-induced RTK for apoptosis resistance. (A) CD44-HA binding, accompanied by activation of CD44-associated SRC, ezrin phosphorylation, and PI3K activation leads to the lipid-raft-integrated assembly of a complex that includes heat shock protein 70 (HSP70), the co-chaperone CDC37, Rho-GEF, Grb2/VAV2, and Gab-1/PI3-kinase (PI3K), which promotes phosphorylation and activation of the receptor tyrosine kinases (RTKs), including ERBB2, ErbB3, EGFR, IGF1R-β, PDGFR-β, and c-MET. CD44-HA binding initiates cross-talk between RTKs, non-RTKs [SRC (Src)] and linker proteins. Studies have indicated that ErbB2 most likely complexes with CD44 via interactions with Grb2 and Vav2, whereas the interaction of PI3K and CD44 is mediated by Gab-1. PI3K activates Akt and downstream anti-apoptotic events, which contribute to drug resistance. However, HA and PI3K stimulate MDR1 expression, and the stimulatory effects of PI3K would be mainly due to its feedback stimulation of HA production by a positive feedback loop. Studies indicate that MDR1 is associated with CD44 in lipid microdomain and can be linked via CD44 with the actin cytoskeleton so that expression of both CD44 and MDR1 are concomitantly regulated. (B) Particularly, in colorectal cancer, the CD44–ERBB2 complex provides a strong apoptotic resistance through stimulation of cyclooxygenase 2 (COX2) transcription via PI3K and β-catenin. COX2-induced PGE2 stimulates HA synthesis and HA-CD44 signaling. CD44v6 also binds hepatocyte growth factor (HGF) and presents it to c-MET. Activation of MET and the downstream signaling cascades require sustained activation of CD44-associated phosphorylated ezrin, radixin, and moesin (ERM) and SRC (Src) signaling via the Ras-MAPK and the PI3K-Akt pathway. Ras-Erk pathway can augment CD44v6 synthesis through a feedback loop between CD44v6 and c-Met/Ras-Erk pathway.
Figure 4 CD44- and CD44v-induced RTK for apoptosis resistance. (A) CD44-HA binding, accompanied by activation of CD44-associated SRC, ezrin phosphorylation, and PI3K activation leads to the lipid-raft-integrated assembly of a complex that includes heat shock protein 70 (HSP70), the co-chaperone CDC37, Rho-GEF, Grb2/VAV2, and Gab-1/PI3-kinase (PI3K), which promotes phosphorylation and activation of the receptor tyrosine kinases (RTKs), including ERBB2, ErbB3, EGFR, IGF1R-β, PDGFR-β, and c-MET. CD44-HA binding initiates cross-talk between RTKs, non-RTKs [SRC (Src)] and linker proteins. Studies have indicated that ErbB2 most likely complexes with CD44 via interactions with Grb2 and Vav2, whereas the interaction of PI3K and CD44 is mediated by Gab-1. PI3K activates Akt and downstream anti-apoptotic events, which contribute to drug resistance. However, HA and PI3K stimulate MDR1 expression, and the stimulatory effects of PI3K would be mainly due to its feedback stimulation of HA production by a positive feedback loop. Studies indicate that MDR1 is associated with CD44 in lipid microdomain and can be linked via CD44 with the actin cytoskeleton so that expression of both CD44 and MDR1 are concomitantly regulated. (B) Particularly, in colorectal cancer, the CD44–ERBB2 complex provides a strong apoptotic resistance through stimulation of cyclooxygenase 2 (COX2) transcription via PI3K and β-catenin. COX2-induced PGE2 stimulates HA synthesis and HA-CD44 signaling. CD44v6 also binds hepatocyte growth factor (HGF) and presents it to c-MET. Activation of MET and the downstream signaling cascades require sustained activation of CD44-associated phosphorylated ezrin, radixin, and moesin (ERM) and SRC (Src) signaling via the Ras-MAPK and the PI3K-Akt pathway. Ras-Erk pathway can augment CD44v6 synthesis through a feedback loop between CD44v6 and c-Met/Ras-Erk pathway.CC BY · PubMed Central
Figure 5 Cross-talk between CD44 and RHAMM interaction with HA affects physiological and cellular functions. Green Track is for extracellular RHAMM signaling involving CD44-HA-mediated pathways. Red track is for intracellular RHAMM signaling. Studies suggest a model for functions of CD44 and RHAMM. The interaction of HA-CD44-RHAMM affects physiological and cellular functions. Cell surface RHAMM interacts with CD44, HA, and growth factor receptors (GFR) to activate protein tyrosine kinase signaling cascades that activate the ERK1/2 MAP kinase cascade in a c-Src/Raf-1/MEK-1/ERK1/2 dependent manner (depicted in green track). In the absence of intracellular RHAMM, this signaling can stimulate the transcription of motogenic effectors to regulate a mitogenic response (cell proliferation/random motility). In the presence of intracellular RHAMM (red track), MEK-1/p-Erk1/2 also binds to a number of protein partners that allows activated RHAMM to enter the nucleus to regulate functions of microtubule dynamics via centrosome structure/function, and cell cycle progression via AURKA, a targeting protein for XkIp2 (TPX2). Activated RHAMM also controls expression of genes involved in cell motility such as PAI-1 and MMP-9.
Figure 5 Cross-talk between CD44 and RHAMM interaction with HA affects physiological and cellular functions. Green Track is for extracellular RHAMM signaling involving CD44-HA-mediated pathways. Red track is for intracellular RHAMM signaling. Studies suggest a model for functions of CD44 and RHAMM. The interaction of HA-CD44-RHAMM affects physiological and cellular functions. Cell surface RHAMM interacts with CD44, HA, and growth factor receptors (GFR) to activate protein tyrosine kinase signaling cascades that activate the ERK1/2 MAP kinase cascade in a c-Src/Raf-1/MEK-1/ERK1/2 dependent manner (depicted in green track). In the absence of intracellular RHAMM, this signaling can stimulate the transcription of motogenic effectors to regulate a mitogenic response (cell proliferation/random motility). In the presence of intracellular RHAMM (red track), MEK-1/p-Erk1/2 also binds to a number of protein partners that allows activated RHAMM to enter the nucleus to regulate functions of microtubule dynamics via centrosome structure/function, and cell cycle progression via AURKA, a targeting protein for XkIp2 (TPX2). Activated RHAMM also controls expression of genes involved in cell motility such as PAI-1 and MMP-9.CC BY · PubMed Central
Figure 6 Drug targeting approaches to exploit HA-CD44 interaction (C) in cancer treatment. (A) HMWHA-CD44v interaction induces inflammation and tumor growth; most common blocking reagents against CD44 isoforms: (B) LMW HA inhibits the binding of HMWHA; (C) sol-CD44 competes with HMWHA to bind with CD44v; (D). CD44-blocking monoclonal antibody (CD44-mAb); (E) antibodies against CD44v6; (F) peptides blocking binding of HA with CD44v6; (G) enzymatic hydrolysis by hyaluronidase cleaves the HMWHA to small fragments and blocks the HA-CD44v6 interaction; (H) targeting HA receptor with HA-drug conjugate; (I) targeting “HA receptor” with “HA nanoparticles.”
Figure 6 Drug targeting approaches to exploit HA-CD44 interaction (C) in cancer treatment. (A) HMWHA-CD44v interaction induces inflammation and tumor growth; most common blocking reagents against CD44 isoforms: (B) LMW HA inhibits the binding of HMWHA; (C) sol-CD44 competes with HMWHA to bind with CD44v; (D). CD44-blocking monoclonal antibody (CD44-mAb); (E) antibodies against CD44v6; (F) peptides blocking binding of HA with CD44v6; (G) enzymatic hydrolysis by hyaluronidase cleaves the HMWHA to small fragments and blocks the HA-CD44v6 interaction; (H) targeting HA receptor with HA-drug conjugate; (I) targeting “HA receptor” with “HA nanoparticles.”CC BY · PubMed Central
Figure 7 Schematic illustration of cellular uptake of plasmid DNA/Tf-PEG-PEI (nanoparticles) polyplexes, their shielding from non-specific interaction, and the mechanism of action of shRNA. Internalization of PEG-shielded and [transferrin receptor (Tf-R)]-targeted polyplexes into target cells occurs by receptor-mediated endocytosis after association of polyplex ligand Tf to Tf-R present on the target cell plasma membrane. Internalized particles are trafficked to endosomes followed by endosomal release of the particles and/or the nucleic acid into cytoplasm. Released siRNA will form a RNA-induced silencing complex and will be guided for cleavage of complementary target mRNA in the cytoplasm. SiRNA (antisense) guide strand will direct the targeted RNAs to be cleaved by RNA endonuclease. Finally, plasmid/Tf-PEG-PEI-nanoparticles delivery in the target cell shows reporter gene expression and activity. The normal tissue cells are not affected because they do not make the targeted CD44 variant. Tf-PEG-PEI nanoparticle coated plasmids (pSico-CD44v6 shRNA/pFabpl-Cre) circulating in blood accumulate at tumor regions enhanced by the EPR effect. Endocytosis mediated by ligand-receptor interactions occurs because the nanoparticles are coated with the Tf-ligand for the Tf-R receptor on the tumor cell surface.
Figure 7 Schematic illustration of cellular uptake of plasmid DNA/Tf-PEG-PEI (nanoparticles) polyplexes, their shielding from non-specific interaction, and the mechanism of action of shRNA. Internalization of PEG-shielded and [transferrin receptor (Tf-R)]-targeted polyplexes into target cells occurs by receptor-mediated endocytosis after association of polyplex ligand Tf to Tf-R present on the target cell plasma membrane. Internalized particles are trafficked to endosomes followed by endosomal release of the particles and/or the nucleic acid into cytoplasm. Released siRNA will form a RNA-induced silencing complex and will be guided for cleavage of complementary target mRNA in the cytoplasm. SiRNA (antisense) guide strand will direct the targeted RNAs to be cleaved by RNA endonuclease. Finally, plasmid/Tf-PEG-PEI-nanoparticles delivery in the target cell shows reporter gene expression and activity. The normal tissue cells are not affected because they do not make the targeted CD44 variant. Tf-PEG-PEI nanoparticle coated plasmids (pSico-CD44v6 shRNA/pFabpl-Cre) circulating in blood accumulate at tumor regions enhanced by the EPR effect. Endocytosis mediated by ligand-receptor interactions occurs because the nanoparticles are coated with the Tf-ligand for the Tf-R receptor on the tumor cell surface.CC BY · PubMed Central
Figure 8 Exploitation of HA-CD44 interaction for anticancer therapy. Left panel shows a schematic diagram for cancer cell internalization of HA conjugated to a drug inhibitor of DNA synthesis. CD44 on the membrane traps the HA-drug conjugate and efficiently internalizes it by endocytosis and forms an endosomal vesicle. This is then transported to the lysosome and fused, and the internalized HA is degraded by hyaluronidase 1 (Hyal-1) into small HA oligosaccharides and then to monosaccharides by lysosomal glycosidases, which ultimately releases the conjugated drug. The drug then goes to the nucleus and inhibits the DNA synthesis. Right panel shows targeting the CD44v6mRNA in cancer cells by CD44v6 shRNA. Plasmids that produce CD44v6 shRNA are coated with transferrin present on the outer surface of the nanoparticles. The transferrin molecules then target the transferrin receptors present in high amounts on the cancer cells. Upon internalization, an endosome forms and the plasmids are released to the nucleus where CD44v6 shRNA is produced by DNA pol III. The shRNA is then exported out of the nucleus by exportin, and the dicer enzyme converts shRNA into CD44v6 siRNA. One of the strands of siRNA will bind to CD44v6 mRNA and form a RISC (RNA-induced silencing complex) that is ultimately degraded. Adapted from our article in the International Journal of Cell Biology.
Figure 8 Exploitation of HA-CD44 interaction for anticancer therapy. Left panel shows a schematic diagram for cancer cell internalization of HA conjugated to a drug inhibitor of DNA synthesis. CD44 on the membrane traps the HA-drug conjugate and efficiently internalizes it by endocytosis and forms an endosomal vesicle. This is then transported to the lysosome and fused, and the internalized HA is degraded by hyaluronidase 1 (Hyal-1) into small HA oligosaccharides and then to monosaccharides by lysosomal glycosidases, which ultimately releases the conjugated drug. The drug then goes to the nucleus and inhibits the DNA synthesis. Right panel shows targeting the CD44v6mRNA in cancer cells by CD44v6 shRNA. Plasmids that produce CD44v6 shRNA are coated with transferrin present on the outer surface of the nanoparticles. The transferrin molecules then target the transferrin receptors present in high amounts on the cancer cells. Upon internalization, an endosome forms and the plasmids are released to the nucleus where CD44v6 shRNA is produced by DNA pol III. The shRNA is then exported out of the nucleus by exportin, and the dicer enzyme converts shRNA into CD44v6 siRNA. One of the strands of siRNA will bind to CD44v6 mRNA and form a RISC (RNA-induced silencing complex) that is ultimately degraded. Adapted from our article in the International Journal of Cell Biology.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 393

  1. Christofori, 2003, Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression, EMBO J, 22, 2318, 10.1093/emboj/cdg228 · DOI
  2. Bissell, 2007, Modelling molecular mechanisms of breast cancer and invasion: lessons from the normal gland, Biochem Soc Trans, 35, 18, 10.1042/BST0350018 · DOI
  3. Camenisch, 2002, Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors, Nat Med, 8, 850, 10.1038/nm742 · DOI
  4. Camenisch, 2000, Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme, J Clin Invest, 106, 349, 10.1172/JCI10272 · DOI · Paper page
  5. Misra, 2011, Hyaluronan-CD44 interactions as potential targets for cancer therapy, FEBS J, 278, 1429, 10.1111/j.1742-4658.2011.08071.x · DOI · Paper page
  6. Ghatak, 2012, Targeting the tumor microenvironment in cancer progression, 729
  7. Meyer, 1934, The polysaccharide of the vitreous humor, J Biol Chem, 107, 629, 10.1016/S0021-9258(18)75338-6 · DOI
  8. Olczyk, 2008, [Hyaluronan: structure, metabolism, functions, and role in wound healing], Postepy Hig Med Dosw (Online), 62, 651
  9. Gandhi, 2008, The structure of glycosaminoglycans and their interactions with proteins, Chem Biol Drug Des, 72, 455, 10.1111/j.1747-0285.2008.00741.x · DOI
  10. Laurent, 1992, Hyaluronan, FASEB J, 6, 2397, 10.1096/fasebj.6.7.1563592 · DOI
  11. Sohara, 2001, Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner, Mol Biol Cell, 12, 1859, 10.1091/mbc.12.6.1859 · DOI
  12. Collis, 1998, Rapid hyaluronan uptake is associated with enhanced motility: implications for an intracellular mode of action, FEBS Lett, 440, 444, 10.1016/S0014-5793(98)01505-1 · DOI
  13. Underhill, 1987, The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity, J Biol Chem, 262, 13142, 10.1016/S0021-9258(18)45179-4 · DOI
  14. Stamenkovic, 1989, A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family, Cell, 56, 1057, 10.1016/0092-8674(89)90638-7 · DOI
  15. Aruffo, 1990, CD44 is the principal cell surface receptor for hyaluronate, Cell, 61, 1303, 10.1016/0092-8674(90)90694-A · DOI
  16. Lesley, 1990, Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1, Exp Cell Res, 187, 224, 10.1016/0014-4827(90)90085-O · DOI
  17. Miyake, 1990, Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition, J Exp Med, 172, 69, 10.1084/jem.172.1.69 · DOI
  18. Ghatak, 2010, Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor, J Biol Chem, 285, 19821, 10.1074/jbc.M110.104273 · DOI
  19. Hardwick, 1992, Molecular cloning of a novel hyaluronan receptor that mediates tumor motility, J Cell Biol, 117, 1343, 10.1083/jcb.117.6.1343 · DOI
  20. Turley, 1992, Hyaluronan and cell locomotion, Cancer Metastasis Rev, 11, 21, 10.1007/BF00047600 · DOI
  21. Turley, 1991, Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells, J Cell Biol, 112, 1041, 10.1083/jcb.112.5.1041 · DOI · Paper page
  22. Tammi, 2002, Hyaluronan and homeostasis: a balancing act, J Biol Chem, 277, 4581, 10.1074/jbc.R100037200 · DOI
  23. Ponta, 2003, CD44: from adhesion molecules to signalling regulators, Nat Rev Mol Cell Biol, 4, 33, 10.1038/nrm1004 · DOI
  24. Naor, 2002, CD44 in cancer, Crit Rev Clin Lab Sci, 39, 527, 10.1080/10408360290795574 · DOI
  25. Naor, 1997, CD44: structure, function, and association with the malignant process, Adv Cancer Res, 71, 241, 10.1016/S0065-230X(08)60101-3 · DOI
  26. Toole, 2001, Hyaluronan in morphogenesis, Semin Cell Dev Biol, 12, 79, 10.1006/scdb.2000.0244 · DOI
  27. Turley, 2002, Signaling properties of hyaluronan receptors, J Biol Chem, 277, 4589, 10.1074/jbc.R100038200 · DOI
  28. Zhang, 1998, The hyaluronan receptor RHAMM regulates extracellular-regulated kinase, J Biol Chem, 273, 11342, 10.1074/jbc.273.18.11342 · DOI
  29. Yang, 1994, Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein, EMBO J, 13, 286, 10.1002/j.1460-2075.1994.tb06261.x · DOI
  30. Day, 1952, The permeability of interstitial connective tissue and the nature of the interfibrillary substance, J Physiol, 117, 1, 10.1113/jphysiol.1952.sp004728 · DOI
  31. Hascall, 1997, Hyaluronan: Structure and Physical Properties
  32. Hascall, 2004, Intracellular hyaluronan: a new frontier for inflammation?, Biochim Biophys Acta, 1673, 3, 10.1016/j.bbagen.2004.02.013 · DOI
  33. Spicer, 2004, Hyaluronan and morphogenesis, Birth Defects Res C Embryo Today, 72, 89, 10.1002/bdrc.20006 · DOI
  34. Heldin, 1993, Synthesis and assembly of the hyaluronan-containing coats around normal human mesothelial cells, Exp Cell Res, 208, 422, 10.1006/excr.1993.1264 · DOI
  35. Evanko, 2004, Intracellular hyaluronan in arterial smooth muscle cells: association with microtubules, RHAMM, and the mitotic spindle, J Histochem Cytochem, 52, 1525, 10.1369/jhc.4A6356.2004 · DOI
  36. Weigel, 1997, Hyaluronan synthases, J Biol Chem, 272, 13997, 10.1074/jbc.272.22.13997 · DOI
  37. Itano, 2008, Simple primary structure, complex turnover regulation and multiple roles of hyaluronan, J Biochem, 144, 131, 10.1093/jb/mvn046 · DOI
  38. Itano, 1999, Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties, J Biol Chem, 274, 25085, 10.1074/jbc.274.35.25085 · DOI · Paper page
  39. Fraser, 1997, Hyaluronan: its nature, distribution, functions and turnover, J Intern Med, 242, 27, 10.1046/j.1365-2796.1997.00170.x · DOI · Paper page
  40. Day, 2002, Hyaluronan-binding proteins: tying up the giant, J Biol Chem, 277, 4585, 10.1074/jbc.R100036200 · DOI · Paper page
  41. McBride, 1979, Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis, J Exp Med, 149, 507, 10.1084/jem.149.2.507 · DOI
  42. Gately, 1984, In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack, J Immunol, 133, 3387, 10.4049/jimmunol.133.6.3387 · DOI
  43. Bastow, 2008, Hyaluronan synthesis and degradation in cartilage and bone, Cell Mol Life Sci, 65, 395, 10.1007/s00018-007-7360-z · DOI
  44. Camenisch, 2000, Hyaluronan: is bigger better?, Am J Respir Cell Mol Biol, 23, 431, 10.1165/ajrcmb.23.4.f201 · DOI
  45. Ghatak, 2014, Periostin induces intracellular cross-talk between kinases and hyaluronan in atrioventricular valvulogenesis, J Biol Chem, 289, 8545, 10.1074/jbc.M113.539882 · DOI
  46. Fox, 1994, Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms, Cancer Res, 54, 4539
  47. Hrabarova, 2011, Pro-oxidative effect of peroxynitrite regarding biological systems: a special focus on high-molar-mass hyaluronan degradation, Gen Physiol Biophys, 30, 223, 10.4149/gpb_2011_03_223 · DOI
  48. Hrabarova, 2012, Free-radical degradation of high-molar-mass hyaluronan induced by ascorbate plus cupric ions: evaluation of antioxidative effect of cysteine-derived compounds, Chem Biodivers, 9, 309, 10.1002/cbdv.201100046 · DOI
  49. Soltes, 2006, Degradative action of reactive oxygen species on hyaluronan, Biomacromolecules, 7, 659, 10.1021/bm050867v · DOI
  50. Knudson, 2002, CD44-mediated uptake and degradation of hyaluronan, Matrix Biol, 21, 15, 10.1016/S0945-053X(01)00186-X · DOI
  51. Jackson, 2004, Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis, APMIS, 112, 526, 10.1111/j.1600-0463.2004.apm11207-0811.x · DOI
  52. Stern, 2006, Hyaluronidases: their genomics, structures, and mechanisms of action, Chem Rev, 106, 818, 10.1021/cr050247k · DOI
  53. Roden, 1989, Enzymic pathways of hyaluronan catabolism, Ciba Found Symp, 143, 60
  54. Frost, 1997, Purification, cloning, and expression of human plasma hyaluronidase, Biochem Biophys Res Commun, 236, 10, 10.1006/bbrc.1997.6773 · DOI
  55. Gmachl, 1993, The human sperm protein PH-20 has hyaluronidase activity, FEBS Lett, 336, 545, 10.1016/0014-5793(93)80873-S · DOI
  56. Lepperdinger, 1998, HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity, J Biol Chem, 273, 22466, 10.1074/jbc.273.35.22466 · DOI
  57. Lin, 1994, A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg, J Cell Biol, 125, 1157, 10.1083/jcb.125.5.1157 · DOI
  58. Bookbinder, 2006, A recombinant human enzyme for enhanced interstitial transport of therapeutics, J Control Release, 114, 230, 10.1016/j.jconrel.2006.05.027 · DOI · Paper page
  59. Provenzano, 2012, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma, Cancer Cell, 21, 418, 10.1016/j.ccr.2012.01.007 · DOI · Paper page
  60. Stern, 2006, Hyaluronan fragments: an information-rich system, Eur J Cell Biol, 85, 699, 10.1016/j.ejcb.2006.05.009 · DOI
  61. Gunthert, 1993, CD44: a multitude of isoforms with diverse functions, Curr Top Microbiol Immunol, 184, 47
  62. Gunthert, 1991, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells, Cell, 65, 13, 10.1016/0092-8674(91)90403-L · DOI
  63. Naor, 2008, Involvement of CD44, a molecule with a thousand faces, in cancer dissemination, Semin Cancer Biol, 18, 260, 10.1016/j.semcancer.2008.03.015 · DOI
  64. Yamada, 2004, Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer, Clin Exp Metastasis, 21, 57, 10.1023/B:CLIN.0000017203.71293.e0 · DOI
  65. Kosaki, 1999, Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity, Cancer Res, 59, 1141
  66. Liu, 2001, Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells, Cancer Res, 61, 5207
  67. Simpson, 2002, Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice, Am J Pathol, 161, 849, 10.1016/S0002-9440(10)64245-9 · DOI
  68. Hall, 1994, Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity, J Cell Biol, 126, 575, 10.1083/jcb.126.2.575 · DOI
  69. Lokeshwar, 2000, Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells, J Biol Chem, 275, 27641, 10.1074/jbc.M003084200 · DOI
  70. Tian, 2013, High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat, Nature, 499, 346, 10.1038/nature12234 · DOI
  71. Itano, 2004, Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation, J Biol Chem, 279, 18679, 10.1074/jbc.M313178200 · DOI
  72. Horton, 1999, Induction and regulation of macrophage metalloelastase by hyaluronan fragments in mouse macrophages, J Immunol, 162, 4171, 10.4049/jimmunol.162.7.4171 · DOI
  73. Noble, 1993, Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages, J Clin Invest, 91, 2368, 10.1172/JCI116469 · DOI
  74. Hodge-Dufour, 1997, Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages, J Immunol, 159, 2492, 10.4049/jimmunol.159.5.2492 · DOI
  75. Beck-Schimmer, 1998, Hyaluronan induces monocyte chemoattractant protein-1 expression in renal tubular epithelial cells, J Am Soc Nephrol, 9, 2283, 10.1681/ASN.V9122283 · DOI
  76. Fitzgerald, 2000, Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells, J Immunol, 164, 2053, 10.4049/jimmunol.164.4.2053 · DOI
  77. Ohkawara, 2000, Activation and transforming growth factor-beta production in eosinophils by hyaluronan, Am J Respir Cell Mol Biol, 23, 444, 10.1165/ajrcmb.23.4.3875 · DOI
  78. West, 1985, Angiogenesis induced by degradation products of hyaluronic acid, Science, 228, 1324, 10.1126/science.2408340 · DOI
  79. West, 1989, Hyaluronan and angiogenesis, Ciba Found Symp, 143, 187
  80. West, 1989, The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity, Exp Cell Res, 183, 179, 10.1016/0014-4827(89)90428-X · DOI
  81. Termeer, 2000, Oligosaccharides of hyaluronan are potent activators of dendritic cells, J Immunol, 165, 1863, 10.4049/jimmunol.165.4.1863 · DOI
  82. Pandey, 2013, The hyaluronan receptor for endocytosis (HARE) activates NF-kappaB-mediated gene expression in response to 40-400-kDa, but not smaller or larger, hyaluronans, J Biol Chem, 288, 14068, 10.1074/jbc.M112.442889 · DOI
  83. Stern, 2003, Devising a pathway for hyaluronan catabolism: are we there yet?, Glycobiology, 13, 105R, 10.1093/glycob/cwg112 · DOI
  84. Ghatak, 2002, Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway, J Biol Chem, 277, 38013, 10.1074/jbc.M202404200 · DOI
  85. Csoka, 1997, Hyaluronidases in tissue invasion, Invasion Metastasis, 17, 297
  86. Uchiyama, 1990, Chemical change involved in the oxidative reductive depolymerization of hyaluronic acid, J Biol Chem, 265, 7753, 10.1016/S0021-9258(19)38993-8 · DOI
  87. Entwistle, 1996, HA receptors: regulators of signalling to the cytoskeleton, J Cell Biochem, 61, 569, 10.1002/(SICI)1097-4644(19960616)61:4569::AID-JCB103.0.CO;2-B · DOI
  88. Weigel, 1989, The specific interaction between fibrin(ogen) and hyaluronan: possible consequences in haemostasis, inflammation and wound healing, Ciba Found Symp, 143, 248
  89. Toole, 1997, Hyaluronan in morphogenesis, J Intern Med, 242, 35, 10.1046/j.1365-2796.1997.00171.x · DOI
  90. Ghatak, 2014, Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-beta1 signaling in interstitial lung disease, J Biol Chem, 289, 7856, 10.1074/jbc.M113.505065 · DOI
  91. Misra, 2008, Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer, Connect Tissue Res, 49, 219, 10.1080/03008200802143356 · DOI
  92. Misra, 2009, Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE, J Biol Chem, 284, 12432, 10.1074/jbc.M806772200 · DOI
  93. Misra, 2012, Delivery Systems Targeting Cancer at the Level of ECM
  94. Misra, 2006, Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells, J Biol Chem, 281, 34936, 10.1074/jbc.C600138200 · DOI
  95. Bourguignon, 2008, Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells, J Biol Chem, 283, 17635, 10.1074/jbc.M800109200 · DOI
  96. Bourguignon, 2003, Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression, J Biol Chem, 278, 29420, 10.1074/jbc.M301885200 · DOI
  97. Toole, 2005, Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions, Cells Tissues Organs, 179, 66, 10.1159/000084510 · DOI
  98. Pilarski, 1994, RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy?, Leuk Lymphoma, 14, 363, 10.3109/10428199409049691 · DOI
  99. Scheibner, 2006, Hyaluronan fragments act as an endogenous danger signal by engaging TLR2, J Immunol, 177, 1272, 10.4049/jimmunol.177.2.1272 · DOI · Paper page
  100. Tremmel, 2009, A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis, Blood, 114, 5236, 10.1182/blood-2009-04-219204 · DOI
  101. Zhuo, 2004, Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex, J Biol Chem, 279, 38079, 10.1074/jbc.R300039200 · DOI
  102. Day, 2005, Hyaluronan cross-linking: a protective mechanism in inflammation?, Trends Immunol, 26, 637, 10.1016/j.it.2005.09.009 · DOI
  103. de la Motte, 2003, Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function, Am J Pathol, 163, 121, 10.1016/S0002-9440(10)63636-X · DOI
  104. Majors, 2003, Endoplasmic reticulum stress induces hyaluronan deposition and leukocyte adhesion, J Biol Chem, 278, 47223, 10.1074/jbc.M304871200 · DOI
  105. Lesley, 2004, TSG-6 modulates the interaction between hyaluronan and cell surface CD44, J Biol Chem, 279, 25745, 10.1074/jbc.M313319200 · DOI
  106. Lauer, 2009, Primary murine airway smooth muscle cells exposed to poly(I,C) or tunicamycin synthesize a leukocyte-adhesive hyaluronan matrix, J Biol Chem, 284, 5299, 10.1074/jbc.M807965200 · DOI
  107. Laurent, 1995, Functions of hyaluronan, Ann Rheum Dis, 54, 429, 10.1136/ard.54.5.429 · DOI
  108. McKee, 1996, Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44, J Clin Invest, 98, 2403, 10.1172/JCI119054 · DOI
  109. Mascarenhas, 2004, Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression, Am J Respir Cell Mol Biol, 30, 51, 10.1165/rcmb.2002-0167OC · DOI
  110. Powell, 2005, Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal, Immunol Res, 31, 207, 10.1385/IR:31:3:207 · DOI
  111. Boodoo, 2006, Differential regulation of hyaluronan-induced IL-8 and IP-10 in airway epithelial cells, Am J Physiol Lung Cell Mol Physiol, 291, L479, 10.1152/ajplung.00518.2005 · DOI
  112. McKee, 1997, Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism, J Biol Chem, 272, 8013, 10.1074/jbc.272.12.8013 · DOI
  113. Horton, 1998, Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages, J Biol Chem, 273, 35088, 10.1074/jbc.273.52.35088 · DOI
  114. Horton, 2000, Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages, Am J Physiol Lung Cell Mol Physiol, 279, L707, 10.1152/ajplung.2000.279.4.L707 · DOI
  115. Casalino-Matsuda, 2004, Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways, J Biol Chem, 279, 21606, 10.1074/jbc.M309950200 · DOI
  116. Bissell, 2002, The organizing principle: microenvironmental influences in the normal and malignant breast, Differentiation, 70, 537, 10.1046/j.1432-0436.2002.700907.x · DOI
  117. Turley, 1985, Glycosaminoglycan production by murine melanoma variants in vivo and in vitro, Cancer Res, 45, 5098
  118. Knudson, 1984, Stimulation of glycosaminoglycan production in murine tumors, J Cell Biochem, 25, 183, 10.1002/jcb.240250402 · DOI
  119. Knudson, 1984, Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis, Proc Natl Acad Sci U S A, 81, 6767, 10.1073/pnas.81.21.6767 · DOI
  120. Zhang, 1995, Hyaluronan on the surface of tumor cells is correlated with metastatic behavior, Cancer Res, 55, 428
  121. Heldin, 2013, Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer, J Biochem, 154, 395, 10.1093/jb/mvt085 · DOI
  122. Itano, 2008, Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression, Cancer Sci, 99, 1720, 10.1111/j.1349-7006.2008.00885.x · DOI
  123. Zhu, 2006, The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix, Stem Cells, 24, 928, 10.1634/stemcells.2005-0186 · DOI
  124. DeAngelis, 2012, Glycosaminoglycan polysaccharide biosynthesis and production: today and tomorrow, Appl Microbiol Biotechnol, 94, 295, 10.1007/s00253-011-3801-6 · DOI
  125. Vigetti, 2014, Metabolic control of hyaluronan synthases, Matrix Biol, 35, 8, 10.1016/j.matbio.2013.10.002 · DOI
  126. Weigel, 2007, Hyaluronan synthases: a decade-plus of novel glycosyltransferases, J Biol Chem, 282, 36777, 10.1074/jbc.R700036200 · DOI
  127. Itano, 2002, Mammalian hyaluronan synthases, IUBMB Life, 54, 195, 10.1080/15216540214929 · DOI
  128. Tolg, 2014, Hyaluronan and RHAMM in wound repair and the “cancerization” of stromal tissues, Biomed Res Int, 2014, 103923, 10.1155/2014/103923 · DOI
  129. Karvinen, 2003, Keratinocyte growth factor stimulates migration and hyaluronan synthesis in the epidermis by activation of keratinocyte hyaluronan synthases 2 and 3, J Biol Chem, 278, 49495, 10.1074/jbc.M310445200 · DOI
  130. Yung, 2000, Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro, Kidney Int, 58, 1953, 10.1111/j.1523-1755.2000.00367.x · DOI
  131. Jacobson, 2000, Expression of human hyaluronan synthases in response to external stimuli, Biochem J, 348, 29, 10.1042/0264-6021:3480029 · DOI
  132. Heldin, 2008, Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis, Connect Tissue Res, 49, 215, 10.1080/03008200802143323 · DOI
  133. Itano, 2002, Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration, Proc Natl Acad Sci U S A, 99, 3609, 10.1073/pnas.052026799 · DOI
  134. Jacobetz, 2013, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut, 62, 112, 10.1136/gutjnl-2012-302529 · DOI · Paper page
  135. Stamenkovic, 1991, The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells, EMBO J, 10, 343, 10.1002/j.1460-2075.1991.tb07955.x · DOI
  136. Lesley, 1992, CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells, Eur J Immunol, 22, 2719, 10.1002/eji.1830221036 · DOI
  137. St Jacques, 1993, CD44 in human placenta: localization and binding to hyaluronic acid, Placenta, 14, 25, 10.1016/S0143-4004(05)80246-2 · DOI
  138. Peach, 1993, Identification of hyaluronic acid binding sites in the extracellular domain of CD44, J Cell Biol, 122, 257, 10.1083/jcb.122.1.257 · DOI
  139. Lesley, 1997, CD44 in inflammation and metastasis, Glycoconj J, 14, 611, 10.1023/A:1018540610858 · DOI
  140. Idzerda, 1989, Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium, Proc Natl Acad Sci U S A, 86, 4659, 10.1073/pnas.86.12.4659 · DOI
  141. Liao, 1995, N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding, J Immunol, 155, 3938, 10.4049/jimmunol.155.8.3938 · DOI
  142. Pure, 1995, Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain, J Exp Med, 181, 55, 10.1084/jem.181.1.55 · DOI
  143. Bajorath, 1998, Identification of CD44 residues important for hyaluronan binding and delineation of the binding site, J Biol Chem, 273, 338, 10.1074/jbc.273.1.338 · DOI
  144. Hofmann, 1991, CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines, Cancer Res, 51, 5292
  145. Zoller, 2011, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, Nat Rev Cancer, 11, 254, 10.1038/nrc3023 · DOI
  146. Heider, 1993, A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps, J Cell Biol, 120, 227, 10.1083/jcb.120.1.227 · DOI
  147. Heider, 2004, CD44v6: a target for antibody-based cancer therapy, Cancer Immunol Immunother, 53, 567, 10.1007/s00262-003-0494-4 · DOI
  148. Tanabe, 1993, Expression of CD44R1 adhesion molecule in colon carcinomas and metastases, Lancet, 341, 725, 10.1016/0140-6736(93)90490-8 · DOI
  149. Wielenga, 1993, Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression, Cancer Res, 53, 4754
  150. Matsumura, 1992, Significance of CD44 gene products for cancer diagnosis and disease evaluation, Lancet, 340, 1053, 10.1016/0140-6736(92)93077-Z · DOI
  151. Koopman, 1993, Activated human lymphocytes and aggressive non-Hodgkin’s lymphomas express a homologue of the rat metastasis-associated variant of CD44, J Exp Med, 177, 897, 10.1084/jem.177.4.897 · DOI
  152. Heider, 1993, Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa, Cancer Res, 53, 4197
  153. Birch, 1991, Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44, Cancer Res, 51, 6660
  154. Haynes, 1991, The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms, Cancer Cells, 3, 347
  155. Lesley, 1993, CD44 and its interaction with extracellular matrix, Adv Immunol, 54, 271, 10.1016/S0065-2776(08)60537-4 · DOI
  156. van der Voort, 1999, Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met, J Biol Chem, 274, 6499, 10.1074/jbc.274.10.6499 · DOI
  157. Skelton, 1998, Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan, J Cell Biol, 140, 431, 10.1083/jcb.140.2.431 · DOI
  158. English, 1998, Site-specific de-N-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding, Cancer Res, 58, 3736
  159. Ruffell, 2005, Chondroitin sulfate addition to CD44H negatively regulates hyaluronan binding, Biochem Biophys Res Commun, 334, 306, 10.1016/j.bbrc.2005.06.108 · DOI
  160. Lesley, 1994, Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response, J Exp Med, 180, 383, 10.1084/jem.180.1.383 · DOI
  161. Yu, 1999, Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion, Genes Dev, 13, 35, 10.1101/gad.13.1.35 · DOI
  162. Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev, 14, 163, 10.1101/gad.14.2.163 · DOI · Paper page
  163. Okamoto, 2002, Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors, Am J Pathol, 160, 441, 10.1016/S0002-9440(10)64863-8 · DOI
  164. Okamoto, 2001, Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway, J Cell Biol, 155, 755, 10.1083/jcb.200108159 · DOI
  165. Cichy, 2003, The liberation of CD44, J Cell Biol, 161, 839, 10.1083/jcb.200302098 · DOI
  166. Echiburu-Chau, 2011, Metastatic suppressor CD44 is related with oxidative stress in breast cancer cell lines, Int J Oncol, 39, 1481, 10.3892/ijo.2011.1154 · DOI
  167. Stoop, 2001, Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice, Arthritis Rheum, 44, 2922, 10.1002/1529-0131(200112)44:122922::AID-ART4803.0.CO;2-7 · DOI
  168. Louderbough, 2011, CD44 promotes epithelial mammary gland development and exhibits altered localization during cancer progression, Genes Cancer, 2, 771, 10.1177/1947601911428223 · DOI
  169. Louderbough, 2011, Understanding the dual nature of CD44 in breast cancer progression, Mol Cancer Res, 9, 1573, 10.1158/1541-7786.MCR-11-0156 · DOI
  170. Wang, 2002, CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice, Am J Pathol, 161, 2219, 10.1016/S0002-9440(10)64498-7 · DOI
  171. Ruiz, 1995, CD44 isoforms during differentiation and development, Bioessays, 17, 17, 10.1002/bies.950170106 · DOI
  172. Kim, 1994, CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation, Arch Biochem Biophys, 310, 504, 10.1006/abbi.1994.1199 · DOI
  173. Wielenga, 1999, Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway, Am J Pathol, 154, 515, 10.1016/S0002-9440(10)65297-2 · DOI · Paper page
  174. Zeilstra, 2014, Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling, Oncogene, 33, 665, 10.1038/onc.2012.611 · DOI
  175. Stauder, 1995, CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor, Blood, 85, 2885, 10.1182/blood.V85.10.2885.bloodjournal85102885 · DOI
  176. Todaro, 2007, Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4, Cell Stem Cell, 1, 389, 10.1016/j.stem.2007.08.001 · DOI
  177. Guo, 2014, Alternative CD44 splicing in intestinal stem cells and tumorigenesis, Oncogene, 33, 537, 10.1038/onc.2013.260 · DOI
  178. Kainz, 1995, Splice variants of CD44 in human cervical cancer stage IB to IIB, Gynecol Oncol, 57, 383, 10.1006/gyno.1995.1159 · DOI
  179. Kainz, 1995, Prognostic value of CD44 splice variants in human stage III cervical cancer, Eur J Cancer, 31A, 1706, 10.1016/0959-8049(95)00353-K · DOI
  180. Hsieh, 1999, Molecular studies into the role of CD44 variants in metastasis in gastric cancer, Mol Pathol, 52, 25, 10.1136/mp.52.1.25 · DOI
  181. Shtivelman, 1991, Expression of CD44 is repressed in neuroblastoma cells, Mol Cell Biol, 11, 5446, 10.1128/MCB.11.11.5446 · DOI
  182. De Marzo, 1998, CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to gleason grade and cytoarchitecture, Prostate, 34, 162, 10.1002/(SICI)1097-0045(19980215)34:3162::AID-PROS23.0.CO;2-K · DOI
  183. Seiter, 1993, Prevention of tumor metastasis formation by anti-variant CD44, J Exp Med, 177, 443, 10.1084/jem.177.2.443 · DOI
  184. Misra, 2008, Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells, J Biol Chem, 283, 14335, 10.1074/jbc.M703811200 · DOI
  185. Pure, 2001, A crucial role for CD44 in inflammation, Trends Mol Med, 7, 213, 10.1016/S1471-4914(01)01963-3 · DOI
  186. Ruffell, 2009, The Regulation and Function of Hyaluronan Binding by CD44 in the Immune System
  187. Siegelman, 1999, Activation and interaction of CD44 and hyaluronan in immunological systems, J Leukoc Biol, 66, 315, 10.1002/jlb.66.2.315 · DOI
  188. Naor, 2007, CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice, Ann N Y Acad Sci, 1110, 233, 10.1196/annals.1423.025 · DOI
  189. Nedvetzki, 2004, RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy, Proc Natl Acad Sci U S A, 101, 18081, 10.1073/pnas.0407378102 · DOI
  190. DeGrendele, 1997, Requirement for CD44 in activated T cell extravasation into an inflammatory site, Science, 278, 672, 10.1126/science.278.5338.672 · DOI
  191. DeGrendele, 1996, CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway, J Exp Med, 183, 1119, 10.1084/jem.183.3.1119 · DOI · Paper page
  192. Clark, 1996, CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma, J Cell Biol, 134, 1075, 10.1083/jcb.134.4.1075 · DOI
  193. Hutas, 2008, CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritis, Blood, 112, 4999, 10.1182/blood-2008-04-150383 · DOI
  194. Khan, 2004, Role of CD44 and hyaluronan in neutrophil recruitment, J Immunol, 173, 7594, 10.4049/jimmunol.173.12.7594 · DOI
  195. McDonald, 2008, Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids, J Exp Med, 205, 915, 10.1084/jem.20071765 · DOI
  196. Cuff, 2001, The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation, J Clin Invest, 108, 1031, 10.1172/JCI200112455 · DOI
  197. Wang, 2002, CD44 deficiency in mice protects brain from cerebral ischemia injury, J Neurochem, 83, 1172, 10.1046/j.1471-4159.2002.01225.x · DOI
  198. Huebener, 2008, CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response, J Immunol, 180, 2625, 10.4049/jimmunol.180.4.2625 · DOI
  199. Mikecz, 1995, Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis, Nat Med, 1, 558, 10.1038/nm0695-558 · DOI
  200. Verdrengh, 1995, Administration of antibodies to hyaluronanreceptor (CD44) delays the start and ameliorates the severity of collagen II arthritis, Scand J Immunol, 42, 353, 10.1111/j.1365-3083.1995.tb03667.x · DOI

200 of 393 shown

Cited by

Sorted by citations

See all 830

Metadata

Authors
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2015-05-06
Volume
6
ISSN
1664-3224
DOI
10.3389/fimmu.2015.00201
PMC
PMC4422082
Cited by
830
References
8

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. https://app.cochat.ai/papers/10.3389/fimmu.2015.00201
The paper
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015). Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2015.00201